TYDEMY Drug Patent Profile
✉ Email this page to a colleague
When do Tydemy patents expire, and when can generic versions of Tydemy launch?
Tydemy is a drug marketed by Lupin Ltd and is included in one NDA.
The generic ingredient in TYDEMY is drospirenone; ethinyl estradiol; levomefolate calcium. There are eleven drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the drospirenone; ethinyl estradiol; levomefolate calcium profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TYDEMY?
- What are the global sales for TYDEMY?
- What is Average Wholesale Price for TYDEMY?
Summary for TYDEMY
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 2 |
| Patent Applications: | 8 |
| DailyMed Link: | TYDEMY at DailyMed |
US Patents and Regulatory Information for TYDEMY
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lupin Ltd | TYDEMY | drospirenone; ethinyl estradiol; levomefolate calcium | TABLET;ORAL | 205948-001 | Dec 12, 2017 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
